What is it about?
To evaluate the efficacy and safety of ribociclib plus letrozole in recurrent low-grade serous ovarian carcinoma, addressing the need for effective chemotherapy-sparing strategies.
Featured Image
Photo by Europeana on Unsplash
Why is it important?
In this multicenter phase II trial, ribociclib plus letrozole achieved a 30.6% objective response rate and 84% clinical benefit rate, with durable responses and a manageable safety profile.
Perspectives
These findings strongly support continued development of cyclin-dependent kinases 4 and 6-endocrine therapy combinations in this less common and relatively chemotherapy-resistant subtype of ovarian cancer.
Professor David Scott Miller
University of Texas Southwestern Medical School
Read the Original
This page is a summary of: Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026), Journal of Clinical Oncology, December 2025, American Society of Clinical Oncology (ASCO),
DOI: 10.1200/jco-25-01348.
You can read the full text:
Contributors
The following have contributed to this page
